Full Description
This is an open access book. With a wealth of exciting data emerging in this rapidly evolving field, this book reviews state-of-the-art knowledge with emphasis on multidisciplinary decision making and management of head and neck cancer. Significant detail is provided on a wide range of topics including: oral potentially malignant disorders, cell-based assays for drug discovery and drug evaluation, the role of precision medicine (genomics and beyond), innovations in systemic therapy (including metronomic chemotherapy and immunotherapy), surgery (including partial laryngeal surgery and quality of reconstruction) and radiotherapy (including FLASH-therapy) in different disease settings taking into account their impact on benefit/risk ratio.
In addition, specific topics such as hypoxia, hyperthermia, intratumoral drug administration, noninvasive biomarkers, local therapy in metastatic head and neck cancer, sentinel lymph node biopsy in cN0 early-stage oral cavity cancer, prognostic factors in HPV-positive oropharyngeal cancer, molecular characterization of salivary gland cancer (including implications for treatment) and strategies to improve outcome in salivary duct carcinoma are discussed.
All disciplines involved in the treatment of head and neck cancer are covered with a focus on translation into daily practice. The 9th-THNO is designed for medical oncologists, head and neck surgeons, radiation oncologists, otolaryngologists, and other medical professionals involved in the treatment and care of patients with head and neck cancer.
Contents
Section 1: From basic science to clinical application.- 1. Oral potentially malignant disorders (OPMD): an update, Ruud Brakenhoff.- 2. The role of artificial intelligence in OPMD.- 3. Treatment of OPMD and first results of immune checkpoint inhibitors.- 4. Innovations in cell-based assays for drug discovery and drug evaluation.- 5. Is the ESCAT ranking of support in head and neck cancer management?.- 6. Mechanism of action and potential use of SMAC mimetics in HNSCC.- 7. Precision medicine beyond genomics.- Section 2: Primary disease.- 8. Sentinel Node Biopsy in cN0 Early-Stage Oral Cavity Cancer: what is the evidence?.- 9. Partial laryngeal surgery in 2023.- 10. Managing the internal carotid artery in head and neck cancer: where are we?.- 11. Improving quality of reconstructive surgery in head and neck cancer.- 12. Innovation in radiotherapy: "FLASH-therapy".- 13. Hypoxia in head and neck cancer: current relevance.- 14. Hyperthermia: a game changer in the management of head and neck cancer?.- Section 3: Primary disease.- 15. Prognostic factors in HPV-positive oropharyngeal cancer: an update.- 16. Immunotherapy and novel agents in locoregionally advanced HNSCC.- 17. Is reducing the extent of local treatments justified after successful neoadjuvant therapy?.- 18. Noninvasive biomarkers predicting outcome in patients with locoregionally advanced HNSCC.- 19. Innovations in head and neck surgery in the 21st century.- 20. Impact of emerging technology developments in proton therapy.- Section 4: Recurrent/Metastatic (R/M) disease.- 21. 50 years of systemic therapy: what have we gained?.- 22. The potential roles of Antibody-Drug Conjugates in head and neck cancer.- 23. Intratumoral drug administration: more potential in head and neck cancer?.- 24. Novel radioenhancer NBTXR3 as a single agent in locally advanced (LA) HNSCC or in combination with anti-PD1 in R/M HNSCC.- 25. Metronomic chemotherapy and immunotherapy: a fascinating approach.- 26. Metastatic head and neck cancer: what is the optimal local treatment?.- Section 5: Salivary Gland cancer.- 27. Molecular characterization of salivary gland cancer and treatment implications.- 28. Salivary duct carcinoma: strategies to improve outcome.
